Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Ionis Pharmaceuticals's Net Income (Continuing Operations) for the
three
months ended in Jun. 2026 was MXN-2,007 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 was MXN-10,173 Mil.
Ionis Pharmaceuticals (MEX:IONS) Net Income (Continuing Operations) Explanation
Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.
Ionis Pharmaceuticals Net Income (Continuing Operations) Related Terms
Ionis Pharmaceuticals Net Income (Continuing Operations) Historical Data
* Premium members only.
The historical data trend for Ionis Pharmaceuticals's Net Income (Continuing Operations) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ionis Pharmaceuticals Net Income (Continuing Operations) Chart
Ionis Pharmaceuticals Net Income (Continuing Operations) Calculation
Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.
Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-10,173 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Income (Continuing Operations) of MXN-10,173 Mil mean?
Ionis Pharmaceuticals (MEX:IONS) has a Net Income (Continuing Operations) of MXN-10,173 Mil as of Jun. 2026. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' Net Income (Continuing Operations) too high?
Ionis Pharmaceuticals' current Net Income (Continuing Operations) is MXN-10,173 Mil. Overall, Ionis Pharmaceuticals has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Net Income (Continuing Operations) compare to KYMR and PRAX?
Ionis Pharmaceuticals' Net Income (Continuing Operations) of MXN-10,173 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Biotechnology company?
A good Net Income (Continuing Operations) depends on the Biotechnology industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Net Income (Continuing Operations) is MXN-10,173 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ionis Pharmaceuticals (MEX:IONS) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN688.07, compared to a current price of MXN1,010.00 — trading 46.8% above its estimated fair value. The current Net Income (Continuing Operations) is MXN-10,173 Mil. Ionis Pharmaceuticals' overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Ionis Pharmaceuticals (MEX:IONS), the current Net Income (Continuing Operations) is MXN-10,173 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ionis Pharmaceuticals (MEX:IONS) Overvalued in 2026?
Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN1,010.00 is trading 46.8% above its estimated GF Value™ of MXN688.07.
GuruFocus considers Ionis Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for MEX:IONS:
Net Income (Continuing Operations): MXN-10,173 Mil
GF Value™: MXN688.07 vs. price of MXN1,010.00 (46.8% above fair value)
No single metric tells the full story. See the MEX:IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
67GF Score
Get the complete analysis for MEX:IONS
Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:IONS has been successfully added to your 
